Global Gastrointestinal Pharmaceuticals Market: By Drug Class (Acid Neutralizers, Antidiarrheal & Laxatives, Antiemetic & Antinauseants, Anti-Inflammatory and Others), By Route of Administration (Oral, Rectal, and Parental), By Distribution Channels (Hospital, Retail & Online Pharmacies), By Application (Inflammatory Bowel Disease, Celiac Disease, Peptic Ulcer Disease, Irritable Bowel Syndrome,Gastroenteritis, and Others), By Mode of Purchase (Prescription and Over the Counter Drugs), and By Regional Analysis (North America, Europe, Asia-Pacific, Middle East & Africa, &South America)—Global Forecast till 2032

Description

Market Overview:

The Global Gastrointestinal PharmaceuticalsMarket was valued at USD 42.0 billion in 2023. It is projected to grow at a compound annual growth rate (CAGR) of 5% during the forecast period of 2024 – 2032, reaching USD 64.5 billion by 2032.

Gastrointestinal therapeutics is a specialized field focused on diagnosing and treating disorders of the gastrointestinal (GI) tract, which includes organs such as the stomach, small intestine, large intestine, and rectum. This field encompasses various treatments designed to alleviate symptoms, improve GI function, and enhance the quality of life for individuals with GI conditions.

Several factors are driving the growth of the gastrointestinal pharmaceuticals market, including the increasing prevalence of GI disorders, greater public awareness of digestive health, and the development of advanced drug formulations.

Market Size for Global Gastrointestinal Pharmaceuticals Market on the Basis of Revenues in USD Bn , 2018-2023

Source: Maven Market Research

Factors leading to the Growth of the Global Gastrointestinal Pharmaceuticals Market

Increasing prevalence of GI disorders and cancer- Rising incidences of gastrointestinal disorders and cancer globally contribute to the growing demand for pharmaceutical interventions targeting these conditions.

Growing trend toward screening and preventive care- A shift in healthcare focus towards early detection and prevention of gastrointestinal diseases drives increased screening initiatives, creating a larger pool of individuals seeking pharmaceutical solutions for preventative measures.

Growing adoption and approval of biological drugs- The expanding use and regulatory approval of biological drugs, including targeted therapies and immunomodulators, offer advanced treatment options for gastrointestinal conditions, driving market growth.

High unmet need- Despite advancements, there remains a significant unmet medical need in gastrointestinal healthcare, spurring research and development efforts and creating opportunities for pharmaceutical companies to address gaps in treatment options.

Restraints for the Global Gastrointestinal Pharmaceuticals Market –

The global gastrointestinal pharmaceuticals market encounters various constraints. Regulatory hurdles and lengthy approval processes increase costs for drug development. Pricing pressures and generic alternatives restrict revenue growth, while adverse effects and patient non-compliance pose challenges to treatment effectiveness. Competition from holistic healthcare trends and limited access to medications in developing regions further impede market expansion.

What is the Current Structure of the Global Gastrointestinal Pharmaceuticals Market?

By Drug Class, Acid Neutralizers Segment held the largest market revenue in the Global Market

The rising demand for preventing gastroesophageal reflux disease has led to increased use of acid neutralizers. Consequently, the Acid Neutralizers segment is expected to dominate the global gastrointestinal pharmaceuticals market during the forecast period. Additionally, the cost efficiency of these neutralizers has significantly contributed to the segment’s strong growth and market presence.

By Route of Administration, the Oral Segment  is dominating the Largest Market Share in the Global Market

The oral segment is projected to be the fastest-growing in the global gastrointestinal pharmaceutical marketduring the forecast period. This growth is driven by the increasing demand for oral medications, their ease of use, and cost-effectiveness. Additionally, the rising acceptance of experimental oral treatments for GI issues is expected to further boost the segment’s expansion.

By Distribution Channel, Drug Stores & Retail Pharmacies Segment Dominated the Largest Market Share in the Global Market

In 2022, drug stores and retail pharmacies held 48.4% of the global gastrointestinal pharmaceuticals market and are expected to stay dominant. Their accessibility ensures easy access to medications and pharmacist advice. Growth drivers include rising demand for OTC drugs, poor dietary habits, increased approval of oral drugs for GI disorders, and the availability of novel medications.

By Applications, Inflammatory Bowel Disease (IBD) Segment dominated the largest CAGR in the Global Market

The Inflammatory Bowel Disease (IBD) segment dominated the global gastrointestinal pharmaceuticals market in 2022 and is expected to continue leading with the highest CAGR during the forecast period. This growth is driven by the increasing prevalence of IBD, including Crohn’s disease and ulcerative colitis. Additionally, advancements in targeted biologic therapies and personalized treatment approaches have significantly enhanced IBD management, further supporting the segment’s growth.

By Mode of Purchase, the Over-the-Counter (OTC) Segment held the largest share in the global market

The over-the-counter drugs segment is poised to be the fastest-growing in the global gastrointestinal pharmaceuticals market based on mode of purchase. This is driven by increasing consumer preference for self-management of common gastrointestinal issues, convenience, and accessibility of over-the-counter medications. Additionally, rising awareness about self-care and wellness and advancements in formulation technologies contribute to the segment’s growth.

By Regional Analysis, the North American Region Registered the Largest Market Share in the Global Market

The North American region currently leads the global gastrointestinal pharmaceutical market and is expected to maintain its dominance through the forecast period. Key factors driving this growth include technological advancements, lifestyle changes leading to a higher incidence of gastrointestinal diseases, an increase in the geriatric and obese populations, and robust research and development activities. The presence of major market players and government initiatives, such as UNICEF and WHO’s Integrated Global Action Plan for Diarrhea, which aims to reduce preventable child deaths through increased awareness and access to treatment, further bolster the market in this region.

Competitive Analysis

Major firms are implementing tactics like alliances, mergers and acquisitions, and new product development. Prominent industry participants, including F. Hoffmann-La Roche AG, Galapagos NV, Pfizer Inc., and AbbVie Inc., are actively engaged in the advancement of innovative treatments for gastrointestinal disorders. For example, AbbVie Inc. got approval from the U.S. FDA in March 2022 for its innovative medication RINVOQ (upadacitinib), which is intended to treat moderately to highly active ulcerative colitis.

Market Segmentation

Global Gastrointestinal Pharmaceuticals Market, ByDrug Class

• Acid Neutralizers
• Antidiarrheal and Laxatives
• Antiemetic and Antinauseants
• Anti-Inflammatory Drugs
• Others

Global Gastrointestinal Pharmaceuticals Market, By Route of Administration

• Oral
• Rectal
• Parental

Global Gastrointestinal Pharmaceuticals Market, By Distribution Channel

• Hospitals Pharmacies
• Drug Stores and Retail Pharmacies
• Online Pharmacies

Global Gastrointestinal Pharmaceuticals Market, By Applications

• Inflammatory Bowel Disease
• Celiac Disease
• Irritable Bowel Syndrome
• Peptic Ulcer Disease
• Gastroenteritis
• Others

Global Gastrointestinal Pharmaceuticals Market, By Mode of Purchase

• Prescription Drugs
• Over the Counter Drugs

Global Gastrointestinal Pharmaceuticals Market, By Regional Analysis

• North America
• United States (U.S.)
• Canada
• Europe
  • Germany
  • United Kingdom (U.K.)
  • France
  • Norway
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Rest of Europe (RoE)
• Asia-Pacific (APAC)
  • China
  • Japan
  • Australia
  • Thailand
  • South Korea
  • India
  • Rest of Asia Pacific
• Middle East & Africa (MEA)
• UAE
• South Africa
• GCC
• Kuwait
• Saudi Arabia
• Latin America
• Brazil
• Argentina
• Rest of Latin America

Major Top Operating Market LeadersInclude

• Abbvie Inc.
• Sanofi
• AstraZeneca
• Boston Scientific Corporation
• Pfizer Incorporation
• Novartis AG
• Takeda Pharmaceutical Company Limited
• Celtrion Healthcare Co. Ltd.
• Bausch Health Companies Inc. (Salix Pharmaceuticals Inc.)
• Cipla Incorporation
• Boehringer Ingelheim
• Sun Pharmaceutical Industries Ltd.
• Bayer AG
• Organon Group of Companies